Combined Therapies for DMD, page-184

Last part of ann back in September:

.......The focus of these Scientific Advice meetings will be on the Phase IIb trial design, dose escalation plans, applicability of the study end-points and the study duration. ANP expects to receive written responses within one month following each meeting.Once national scientific advice is obtained the Company intends to seek advice from the European Medicines Agency (EMA) with the purpose of receiving the EMA’s acceptance of the overall development program for ATL1102 in DMD, in particular the Phase IIb clinical study design and path for product registration.Mark Diamond, CEO of Antisense Therapeutics said: “We are pleased to confirm this important step of the commencement of regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 in DMD and we look forward to reporting on the progress of these interactions in due course’.

.......Diamond is looking forward to reporting on the progress “in due course”
I wonder when is the Diamond’s due course